# Pelabresib

Source: https://onco.cc/drugs/pelabresib/  
OnCo record `pelabresib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Pelabresib is an experimental small-molecule drug from Novartis Pharmaceuticals in phase 3 trials, with its target not yet stated publicly.

## Summary

Pelabresib (CPI-0610) is a small-molecule drug developed by Novartis Pharmaceuticals. The sponsor describes its target as BET (bromodomain and extraterminal protein), which OnCo does not yet have a target page for. The sponsor states: A small-molecule BET protein inhibitor. ClinicalTrials.gov describes the intervention as: Small molecule inhibitor of bromodomain and extraterminal (BET) protein. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06401356 (An Extension Study for Patients Previously Enrolled in Studies With Pelabresib). The largest, NCT06401356, plans to enrol 50 participants with primary completion expected 2027-06-02. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Code: CPI-0610
- Modality: small molecule
- Mechanism: A small-molecule BET protein inhibitor.

## Sources

- ClinicalTrials.gov: trials of Pelabresib: https://clinicaltrials.gov/search?intr=CPI-0610
- Sponsor pipeline page: https://www.novartis.com/research-development/novartis-pipeline

## Connected records

- cancers: [Primary myelofibrosis](https://onco.cc/cancers/primary-myelofibrosis/)
- targets: [BRD4](https://onco.cc/targets/brd4/)
- companies: [Novartis](https://onco.cc/companies/novartis/)
- trials: [An Extension Study for Patients Previously Enrolled in Studies With Pelabresib](https://onco.cc/trials/nct06401356/), [MANIFEST-2](https://onco.cc/trials/manifest-2/)

---
JSON: https://onco.cc/api/v1/entities/pelabresib.json